| Oct 15 |
Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's
|
| Oct 15 |
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
|
| Oct 3 |
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
|
| Oct 2 |
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
|
| Sep 30 |
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
|
| Sep 27 |
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
|
| Sep 5 |
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 22 |
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders
|
| Aug 15 |
Annovis Bio GAAP EPS of -$0.44 beats by $0.09
|
| Aug 15 |
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
|
